A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members. "We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," write Sonal Singh, M.D., M.P.H., assistant professor of internal medicine, and Curt D. Furberg, M.D., Ph.D., professor of public health sciences. Rosiglitazone and pioglitazone are the two major thiazolidinediones. In the editorial Singh and Furberg say, "At this time, justification for use of thiazolidinediones is very weak to non-existent."
Read article at physorg.com
Friday, 5 September 2008
A class of type 2 diabetes drugs carries significant cardiovascular risks
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment